Cognizance Technologies, LLC

Cognizance Technologies, LLC, an SBA-certified Economically Disadvantaged Women-Owned Small Business (EDWOSB) and Women-Owned Small Business (WOSB) based in Clarksburg, Maryland, operates predominantly as a subcontractor (68% of recent awards) across IT service delivery, data platform operations, and regulatory support functions, with a nascent prime portfolio anchored to two NASA SEWP VI GWAC seats and multiple FDA blanket purchase agreements. The company is also minority-owned (Subcontinent Asian American) and self-certified as a small disadvantaged business; recent awards split between set-aside and full-and-open categories, with woman-owned and total small business set-asides appearing across FDA and NIAID vehicles.

Customer concentration skews heavily toward civilian health and commerce agencies. The top five funding entities account for 97% of recent awards by count, led by the Department of Commerce US Patent and Trademark Office (22 awards, dollar magnitude not provided), the Food and Drug Administration (8 awards, $152.6 million combined potential value), the National Institute of Allergy and Infectious Diseases (2 awards, $197.1 million), and NASA (2 awards, $40 billion). The potential-value ranking diverges sharply from award count: NASA's two SEWP VI GWAC positions represent $40 billion in combined ceiling (though only recently awarded in November 2026), while FDA's eight task orders and BPA calls total $152.6 million, and NIAID's two awards total $197.1 million. The stark gap reflects Cognizance's recent acquisition of two governmentwide vehicle positions rather than near-term task-order velocity against them.

Cognizance holds positions on the NASA SEWP VI GWAC (two seats — one Partial Small Business, one Total Small Business, both with $20 billion ceilings through October 2036), the GSA Multiple Award Schedule (14 task orders, $366.2 million combined potential value), and four Alliant II task orders. The company operates under a $99.9 million single-award FDA Regulatory Review Support BPA (through January 2030) and a $191.5 million multiple-award NIAID Enabling and Advancing Technology (NEAT) BPA (through September 2029). Prime delivery-order and BPA-call work with FDA includes a $16.4 million Sentinel 3.0 FDA Data Platform Operations, Maintenance, and Analytics Support task order (through August 2031), a $5.3 million Research Tracking System Support Services delivery order (through August 2028), a $2.7 million clinical and nonclinical services BPA call under Regulatory Review Support (through September 2027), and a $1.7 million Center for Drug Evaluation and Research Operations and Customer Support service desk delivery order under the MAS (through September 2028). A $5.6 million NIAID audiovisual events support services BPA call carries performance through July 2029.

In its subcontractor role, Cognizance works almost exclusively under Halvik LLC on Patent Business Content Management Services (PBCMS) and International Data Exchange Biosequence initiatives — the source lists repeated funding modifications and option exercises through mid-2026 — and appears on smaller Accenture Federal Services LLC sub-awards for patent-management and international-data-exchange work. SCI-reportable federal services activity remains nascent: the vendor appears in SCI records as a subcontractor on 27 contracts (1 as prime) from FY2022–FY2025, with reported FTE delivery of 7.0 in FY2022, 13.1 in FY2024, and 15.3 in FY2025 (indicating sub-role scaling), but SCI-reported prime invoicing was zero across the period — reflecting the vendor's very recent transition to prime status on FDA and NIAID vehicles.

GSA Schedule labor offerings span 102 categories priced from $58.17/hr (junior functional analyst, bachelor's degree, no clearance) to $453.57/hr (emerging technology engineer subject matter expert, master's degree, ten years' experience, no clearance), with mid-range pricing in the $125–$185/hr band for project managers and solution architects. The portfolio supports software development, data engineering, cybersecurity, and technical consulting roles; notably, Cognizance does not offer cleared labor slots on its GSA listing. Capability framing from recent awards centers on FDA regulatory data systems, clinical informatics, IT platform operations and maintenance, audiovisual event production services, and patent-management systems development — positioning aligned to civilian health-research and intellectual-property missions rather than defense or national-security domains.

Activity has accelerated sharply: one award in 2018 through 2023, then thirteen in 2024, eleven in 2025, and eleven in 2026 year-to-date, with four awards (combined potential value $11.1 million) facing ultimate completion within the next twenty-four months and therefore exposed to recompete. The massive potential-value figure ($40.35 billion combined across all awards) reflects the very recent SEWP VI GWAC ceilings, which dwarf near-term invoicing: SCI-obligated dollars total only $21.7 million across the portfolio, indicating the vendor has only begun to draw task orders against its large vehicles. For competitive-intelligence purposes, Cognizance represents an emerging prime in civilian IT modernization and data-platform services with women-owned and small-business set-aside positioning and deep FDA and NIH customer relationships; for partnership pursuit, the SEWP VI positions and FDA/NIAID BPA footprint offer teaming upside, though near-term revenue realization remains constrained by the absence of substantial task-order execution history on the new vehicles.

Cognizance Technologies, LLC. (CT), provides best-in-class information technology (IT) solutions, that breed innovation and continuous growth. Solutions in the Clinical Research Informatics, Engineering, Consulting, DevOps Services, Cyber Security, Data Analytics and other areas that support our clients which include Dept. of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), the National Institutes of Health (NIH), Census Bureau (Census), Centers for Medicare & Medicaid Services (CMS), Department of Veterans Affairs (VA), Internal Revenue Services (IRS) and Food and Drug Administration (FDA).